sever
acut
respiratori
syndrom
sar
emerg
infecti
diseas
pose
major
threat
health
peopl
worldwid
etiolog
agent
novel
coronaviru
sarsassoci
coronaviru
sarscov
infect
sarscov
incub
period
rang
day
follow
wide
spectrum
symptom
sign
characterist
present
fever
dyspnea
progress
chang
radiograph
find
andor
respiratori
failur
recent
studi
report
decreas
sarscov
load
preced
diseas
progress
suggest
overexuber
immun
respons
rather
uncontrol
viral
replic
may
contribut
progress
damag
lung
patholog
investig
sar
pneumonia
reveal
hemophagocytosi
reminisc
pneumonia
due
influenza
viru
suggest
proinflammatori
cytokin
dysregul
howev
littl
known
tempor
relationship
viral
load
cytokin
dysregul
clinic
progress
moreov
effect
ribavirin
therapi
viral
load
vivo
remain
larg
unclear
use
quantit
realtim
rtpcr
measur
sarscov
load
sequenti
throatwash
specimen
obtain
patient
probabl
sar
examin
relationship
ribavirin
proinflammatori
cytokin
diseas
progress
throatwash
specimen
chosen
report
high
posit
rate
sarscov
among
patient
probabl
sar
technic
perspect
throatwash
specimen
easier
collect
current
recommend
specimen
includ
nasopharyng
aspir
swab
specimen
oropharyng
swab
specimen
method
studi
includ
adult
patient
met
world
health
organ
clinic
case
definit
probabl
sar
admit
negativepressur
ventil
room
nation
taiwan
univers
hospit
taipei
april
april
sar
outbreak
taipei
case
sar
confirm
laboratori
test
first
day
fever
defin
day
ill
sequenti
chest
radiographi
routin
laboratori
test
perform
least
twice
per
week
oral
ribavirin
given
day
unless
advers
effect
note
methylprednisolon
administ
second
week
patient
first
week
patient
rapidli
progress
diseas
cours
describ
elsewher
intraven
immunoglobulin
ivig
given
patient
sever
leukopenia
thrombocytopenia
mark
progress
lung
lesion
consent
patient
throatwash
specimen
obtain
gargl
ml
normal
salin
collect
everi
day
first
week
hospit
everi
day
thereaft
discharg
accord
guidelin
aerosolgener
procedur
sampl
transfer
biosafeti
level
laboratori
store
use
thaw
throatwash
specimen
centrifug
g
min
obtain
supernat
subject
viral
rna
extract
aliquot
viral
rna
known
amount
rna
quantifi
realtim
rtpcr
assay
describ
elsewher
lower
limit
detect
copi
per
ml
throat
wash
level
proinflammatori
measur
commerci
elisa
kit
endogen
result
demograph
inform
laboratori
find
patient
sar
summar
tabl
among
laboratori
test
report
abnorm
result
case
sar
lymphopenia
elev
lactat
dehydrogenas
ldh
level
found
case
examin
nadir
lymphocyt
count
patient
lymphopenia
occur
median
day
rang
day
ill
peak
ldh
level
occur
median
day
rang
day
ill
sequenti
chest
radiograph
patient
also
evalu
radiologist
determin
radiograph
maximum
pulmonari
infiltr
occur
median
day
rang
day
ill
viral
load
sequenti
throatwash
sampl
obtain
patient
next
examin
tabl
peak
viral
load
rang
copiesml
within
rang
report
elsewher
correl
peak
viral
load
nadir
lymphocyt
count
peak
ldh
level
r
p
respect
simpl
linear
regress
peak
viral
load
occur
mean
day
rang
day
ill
earlier
day
report
elsewher
interest
time
paramet
clinic
lymphocyt
count
peak
ldh
level
maximum
pulmonari
behind
peak
viral
load
median
day
day
day
respect
find
indic
sar
progress
viral
load
decreas
evalu
effect
ribavirin
therapi
vivo
examin
viral
load
pattern
relationship
ribavirin
use
shown
figur
although
describ
elsewher
invert
vshape
viral
load
pattern
primarili
singl
peak
seen
patient
patient
pattern
peak
found
patient
g
h
find
suggest
viral
load
pattern
vari
among
differ
patient
patient
protract
complex
profil
compar
find
ribavirin
use
decreas
viral
load
found
case
patient
b
c
f
howev
viral
load
remain
high
despit
day
ribavirin
therapi
patient
e
h
patient
g
viral
load
decreas
administr
ribavirin
increas
decreas
ribavirin
receiv
find
suggest
ribavirin
effect
reduc
viral
load
patient
studi
next
investig
tempor
relationship
peak
viral
load
proinflammatori
cytokin
level
includ
progress
lung
lesion
contrast
level
level
detect
patient
therefor
analyz
elev
level
gener
parallel
level
although
delay
increas
day
ill
found
case
patient
f
h
absenc
nosocomi
infect
identifi
insult
figur
overal
peak
andor
elev
level
concur
peak
viral
load
preced
concur
maximum
pulmonari
infiltr
figur
note
elev
level
associ
second
viral
load
peak
observ
patient
g
h
probabl
steroid
use
day
day
respect
tempor
relationship
peak
viral
load
well
subsequ
develop
maximum
pulmonari
infiltr
nadir
lymphocyt
count
peak
ldh
level
summar
figur
find
suggest
initi
viral
replic
lead
activ
proinflammatori
cytokin
togeth
factor
contribut
diseas
progress
discuss
report
ribavirin
inhibit
replic
sarscov
vitro
previous
peiri
et
al
examin
viral
load
pattern
patient
receiv
ribavirin
steroid
therapi
viral
load
analyz
respect
exact
time
cours
therapi
patient
effect
ribavirin
viral
load
address
studi
examin
effect
ribavirin
viral
load
vivo
despit
small
sampl
size
studi
close
monitor
viral
load
ribavirin
use
patient
report
differ
profil
viral
load
cours
infect
use
ribavirin
result
reduct
viral
load
patient
studi
whether
ribavirin
use
associ
high
mortal
among
patient
sar
requir
investig
first
studi
investig
tempor
relationship
viral
load
proinflammatori
cytokin
clinic
progress
although
variat
cytokin
profil
analysi
reveal
common
pictur
indic
elev
andor
level
subsequ
peak
viral
replic
involv
pulmonari
progress
figur
similarli
occurr
nadir
lymphocyt
count
peak
ldh
level
lag
behind
peak
viral
load
level
figur
suggest
immunemedi
process
involv
lymphopenia
tissu
damag
patient
sar
note
nadir
lymphocyt
count
seem
correl
peak
viral
load
p
rais
possibl
direct
effect
viral
replic
lymphopenia
taken
togeth
find
support
hypothesi
viral
replic
phase
follow
immun
respons
phase
pathogenesi
sar
moreov
find
provid
import
inform
therapeut
strategi
sar
includ
antivir
immunebas
regimen
steroid
ivig
convalescentphas
serum
infus
regard
convalescentphas
serum
infus
also
examin
igg
seroconvers
patient
indirect
immunofluoresc
assay
describ
elsewher
shown
figur
seroconvers
correl
decreas
viral
load
case
howev
delay
decreas
viral
load
found
patient
e
f
viral
load
remain
high
patient
h
presenc
antibodi
although
studi
preliminarili
suggest
efficaci
convalescentphas
serum
infus
observ
suggest
develop
antibodi
may
correl
clearanc
viru
taken
consider
use
convalescentphas
serum
infus
therapeut
strategi
